EN DE
STOCK COMPARISON

Amgen vs AstraZeneca: Fair Value & Quality

Both stocks run through our valuation models. Here is how Amgen (AMGN) and AstraZeneca (AZN) compare, as of Sep 4, 2026.

As of Sep 4, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Amgen trades at $444 versus a fair value of $252 (-43%), while AstraZeneca trades at $165 versus $127 (-23%).
Amgen
AMGN · USD · Health Care
-43%
upside to fair value
overvalued
Price$444
Fair Value$252
Quality63/100
AstraZeneca
AZN · USD · Health Care
-23%
upside to fair value
overvalued
Price$165
Fair Value$127
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AmgenAstraZeneca
Valuation
25.3×P/E (TTM)24.8×
5.27×P/S (TTM)4.49×
22.65×P/B5.58×
14.0×EV/EBITDA14.5×
2.02×PEG1.36×
−43.3%Fair value upside−22.7%
2.2%Dividend yield1.9%
$9.66Dividend per share$3.20
Profitability
34%Operating margin28%
0.81×EBIT margin trend (5Y)1.21×
101%Return on equity23%
8%Return on assets8%
Growth
6%Revenue growth (YoY)13%
11.8%Avg. growth/yr (3Y)9.8%
7.6%Avg. growth/yr (5Y)17.2%
+2.0%Value creation/yr+46.8%
Balance & size
3.9×Interest coverage (EBIT/interest)8.1×
5.78×Debt / equity0.51×
$196BMarket cap$271B
healthyGrowth qualityhealthy

AstraZeneca leads: 4 to 10 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Amgenof which business quality 60 · market factors 87 AstraZenecaof which business quality 65 · market factors 49
ProfitabilityMargins and returns on capital today
64
63
Quality GrowthAre margins and returns improving?
79
65
CashflowEarnings quality: real cash, not paper profit
78
63
Fin. StrengthBalance sheet, leverage, solvency risk
20
60
InvestmentDisciplined investing over empire-building
42
60
Low VolatilityCalm price path (market factor)
86
85
MomentumPrice trend over the last 3–12 months (market factor)
80
31
52W MomentumDistance to the 52-week high (market factor)
100
39
Net IssuanceBuybacks instead of dilution
81
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAmgenPrice $444AstraZenecaPrice $165
DCF Models-38%below the price$275-30%below the price$116
Earnings-Based-66%below the price$151-63%below the price$60.23
Dividend Discount-62%below the price$167n/a
Multiples-44%below the price$249-24%below the price$125
Asset-Based-98%below the price$10.75-87%below the price$21.03
Growth DCF-52%below the price$214-39%below the price$100
Economic Profit-71%below the price$129-54%below the price$75.73
Growth Earnings-41%below the price$261-22%below the price$129
Minimum-98%below the price$10.75-87%below the price$21.03
Maximum-38%below the price$275-22%below the price$129
Median-57%below the price$190-39%below the price$100
Geometric mean-69%below the price$138-52%below the price$78.30

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Amgen: 26 of 26 models see the stock below the current price.

AstraZeneca: 24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Amgen
Bear $135Fair Value $252Bull $340
$444 = current price (white tick)
AstraZeneca
Bear $72.51Fair Value $127Bull $173
$165 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Amgen · Health Care

Quality score63 · Top 25%
Fair value upside-43% · below median

AstraZeneca · Health Care

Quality score69 · Top 25%
Fair value upside-23% · above median

Bottom line

As of Sep 4, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Amgen trades at $444 versus a fair value of $252 (-43%), while AstraZeneca trades at $165 versus $127 (-23%).

AstraZeneca has the higher quality score (69/100).

See the full analysis →
Amgen · AstraZeneca

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Amgen

Amgen vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth Group

Related to AstraZeneca

AstraZeneca vs UnitedHealth GroupMerck & Company vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.